Volume 133, Issue 3, Pages 364-370 (March 2014) Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - Safety and efficacy in 1,032 patients with hematologic malignancy  Hidesaku Asakura, Hoyu Takahashi, Hajime Tsuji, Tadashi Matsushita, Hideyuki Ninomiya, Goichi Honda, Jun Mimuro, Yutaka Eguchi, Isao Kitajima, Yoichi Sakata  Thrombosis Research  Volume 133, Issue 3, Pages 364-370 (March 2014) DOI: 10.1016/j.thromres.2013.12.033 Copyright © 2014 Elsevier Ltd Terms and Conditions

Fig. 1 The clinical course of bleeding symptoms with respect to platelet counts at the start of TM-α administration. (A) Bleeding symptoms at baseline (n=1,020). (B) Clinical course of bleeding symptoms after the start of TM-α administration (n=325). No significant difference in the progression rate of bleeding symptoms was observed between the three platelet-count groups (chi-square test). PLT: platelet. Thrombosis Research 2014 133, 364-370DOI: (10.1016/j.thromres.2013.12.033) Copyright © 2014 Elsevier Ltd Terms and Conditions

Fig. 2 The changes in hemostatic molecular markers before and after the administration of TM-α according to the clinical course of the underlying disease. Imp: The subject group whose underlying disease was improved, Unch+Exa: The subject group whose underlying disease was unchanged or exacerbated. The box presents the interquartile range (25th to 75th percentile) and the line within this box is the median value. The small hatched box represents the normal range. *p<0.05; **p<0.01; n.s.=not significant, Wilcoxon signed-rank test. Thrombosis Research 2014 133, 364-370DOI: (10.1016/j.thromres.2013.12.033) Copyright © 2014 Elsevier Ltd Terms and Conditions

Supplementary Fig. S1 The relationship between DIC score and survival rate after TM-α treatment. DIC: disseminated intravascular coagulation. Thrombosis Research 2014 133, 364-370DOI: (10.1016/j.thromres.2013.12.033) Copyright © 2014 Elsevier Ltd Terms and Conditions